المؤلفون: Hidalgo Figueroa, María, Salazar Couso, Alejandro, Romero López Alberca, Cristina, MacDowell, Karina S., García-Bueno, Borja, Bioque, Miquel, Bernardo, Miquel, Parellada, M., González-Pinto, Ana, García Portilla, María Paz, Lobo, A., Rodríguez-Jiménez, Roberto, Berrocoso Domínguez, Esther María, Leza, Juan Carlos

المساهمون: Estadística e Investigación Operativa, Neurociencias, Psicología

المصدر: International Journal of Neuropsychopharmacology - 2023, Vol. 26 n. 11, pp. 796-807

مصطلحات موضوعية: First-episode psychosis, prolactin, oxytocin, homocysteine, cognition

الوصف: Background: The clinical debut of schizophrenia is frequently a first episode of psychosis (FEP). As such, there is considerable interest in identifying associations between biological markers and clinical or cognitive characteristics that help predict the progression and outcome of FEP patients. Previous studies showed that high prolactin, low oxytocin, and high homocysteine are factors associated with FEP 6 months after diagnosis, at which point plasma levels were correlated with some clinical and cognitive characteristics. Methods: We reexamined 75 patients at 12 months after diagnosis to measure the evolution of these molecules and assess their association with clinical features. Results: At follow-up, FEP patients had lower prolactin levels than at baseline, and patients treated with risperidone or paliperidone had higher prolactin levels than patients who received other antipsychotic agents. By contrast, no changes in oxytocin and homocysteine plasma levels were observed between the baseline and follow-up. In terms of clinical features, we found that plasma prolactin and homocysteine levels were correlated with the severity of the psychotic symptoms in male FEP patients, suggesting that they might be factors associated with psychotic symptomatology but only in men. Together with oxytocin, these molecules may also be related to sustained attention, verbal ability, and working memory cognitive domains in FEP patients. Conclusion: This study suggests that focusing on prolactin, oxytocin, and homocysteine at a FEP may help select adequate pharmacological treatments and develop new tools to improve the outcome of these patients, where sex should also be borne in mind.

وصف الملف: application/pdf

العلاقة: info:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 (ISCIII)/PI19%2F00766/ES/FACTORES QUE INFLUYEN EN LA FUNCIONALIDAD EN LA COMUNIDAD DE PACIENTES CON PRIMEROS EPISODIOS PSICOTICOS: ESTUDIO LONGITUDINAL DE NEUROCOGNICION, COGNICION SOCIAL Y SINTOMAS CLINICOS (PEP2F)/; info:eu-repo/grantAgreement/Junta de Andalucia//FEDER-UCA18-106933; http://hdl.handle.net/10498/31857Test

الإتاحة: https://doi.org/10.1093/IJNP/PYAD051Test
http://hdl.handle.net/10498/31857Test

المؤلفون: BIOQUE, MIQUEL, MORENO, MARÍA JOSÉ, GÓMEZ-LUS, SUSANA, RAMOS, MARÍA ISABEL

المصدر: Journal of Psychiatric Practice ; volume 30, issue 2, page 82-94 ; ISSN 1538-1145

الوصف: Objective: The two-injection start (TIS) initiation regimen was recently approved for aripiprazole once monthly 400 mg (AOM400), with potential benefits in adherence. The SaTISfy study described in this article analyzed Spanish psychiatrists’ perspectives on hospitalization lengths of stay, schizophrenia management, and the use of AOM400-TIS. Methods: The authors describe an ecological study of aggregated data collected using a 41-question survey. Fifty psychiatrists were asked to provide their perceptions of their patients with schizophrenia and treatment with AOM400. Results: The psychiatrists reported that lack of treatment adherence was the main reason for hospitalization for 58.3% of their patients diagnosed with schizophrenia. Aripiprazole, in any formulation, was the most commonly prescribed therapeutic option, being prescribed for a mean (SD) of 2.5 (0.9) out of 5 patients, while 98% of psychiatrists chose AOM400-TIS for patients who failed to adhere to previous treatments. Patients with schizophrenia, regardless of their treatment, were hospitalized for an average of 17.7 (3.93) days versus patients with schizophrenia treated with AOM400-TIS, who were hospitalized for an average of 14.2 (4.18) days, a reduction of 3.5 (3.86) days. Patients treated with AOM400-TIS showed a reduction of 5 (4.18) days compared with the mean national duration of hospitalization for acute patients in psychiatry units in Spain (19.18 d). The surveyed psychiatrists reported that AOM400-TIS improved safety and tolerability. Most of the psychiatrists were satisfied with the administration and results of AOM400-TIS. Most of the psychiatrists (90%) also reported that fewer health care resources were consumed with AOM400-TIS, mainly due to a reduction in hospitalization days and in the use of concomitant medications. Conclusions: AOM400-TIS was considered to have a positive impact on the duration of hospitalization and thus on the use of health care resources. There was a positive perception of adherence, safety, and tolerability ...

الإتاحة: https://doi.org/10.1097/pra.0000000000000776Test

المؤلفون: Bergé, Daniel, Mané, Anna, Lesh, Tyler A, Bioque, Miquel, Barcones, Fe, Gonzalez-Pinto, Ana Maria, Parellada, Mara, Vieta, Eduard, Castro-Fornieles, Josefina, Rodriguez-Jimenez, Roberto, García-Portilla, Maria Paz, Usall, Judith, Carter, Cameron S, Cabrera, Bibiana, Bernardo, Miguel, Janssen, Joost, Mezquida, Gisela, Amoretti, Silvia, Pina-Camacho, Laura, Arango, Celso, González-Ortega, I, García, S, De-la-Cámara, C, Fayed, N, Sanjuan, Julio, Aguilar, EJ, Guo, Joyce Y, Salgado, Purificación, Raduà, Joquim, Sánchez-Moreno, J, de la Serna, Elena, Baeza, Ima, Contreras-Fernández, Fernando, Saiz-Masvidal, C, González-Blanco, L, Jiménez-Treviño, L, Dompablo, M, Torío, I, Butjosa, A, Rubio-Abadel, E, Sarró, S, Pomarol-Clotet, E

المصدر: Schizophrenia Bulletin. 46(4)

مصطلحات موضوعية: Clinical Research, Prevention, Neurosciences, Schizophrenia, Mental Health, Brain Disorders, Serious Mental Illness, Biomedical Imaging, 2.1 Biological and endogenous factors, Aetiology, Mental health, Adolescent, Adult, Body Water, Child, Cross-Sectional Studies, Female, Gray Matter, Humans, Longitudinal Studies, Magnetic Resonance Imaging, Male, Psychotic Disorders, White Matter, Young Adult, PEPs group, Medical and Health Sciences, Psychology and Cognitive Sciences, Psychiatry

الوصف: Recent diffusion imaging studies using free-water (FW) elimination have shown increased FW in gray matter (GM) and white matter (WM) in first-episode psychosis (FEP) and lower corrected fractional anisotropy (FAt) in WM in chronic schizophrenia. However, little is known about the longitudinal stability and clinical significance of these findings. To determine tissue-specific FW and FAt abnormalities in FEP, as part of a multicenter Spanish study, 132 FEP and 108 healthy controls (HC) were clinically characterized and underwent structural and diffusion-weighted MRI scanning. FEP subjects were classified as schizophrenia spectrum disorder (SSD) or non-SSD. Of these subjects, 45 FEP and 41 HC were longitudinally assessed and rescanned after 2 years. FA and FW tissue-specific measurements were cross-sectional and longitudinally compared between groups using voxel-wise analyses in the skeletonized WM and vertex-wise analyses in the GM surface. SSD and non-SSD subjects showed (a) higher baseline FW in temporal regions and in whole GM average (P.adj(SSD vs HC) = .003, P.adj(Non-SSD vs HC) = .040) and (b) lower baseline FAt in several WM tracts. SSD, but not non-SSD, showed (a) higher FW in several WM tracts and in whole WM (P.adj(SSD vs HC)= .049) and (b) a significant FW decrease over time in temporal cortical regions and in whole GM average (P.adj = .011). Increased extracellular FW in the brain is a reliable finding in FEP, and in SSD appears to decrease over the early course of the illness. FAt abnormalities are stable during the first years of psychosis.

وصف الملف: application/pdf

الوصول الحر: https://escholarship.org/uc/item/7dg822gzTest

المؤلفون: Segura, Alex-Gonzalez, Prohens, Llucia, Mezquida, Gisela, Amoretti, Silvia, Bioque, Miquel, Ribeiro, Maria, Gurriaran-Bas, Xaquin, Rementeria, Lide, Berge, Daniel, Rodriguez-Jimenez, Roberto, Roldan, Alexandra, Pomarol-Clotet, Edith, Ibanez, Angela, Usall, Judith, Garcia-Portilla, Maria Paz, Cuesta, Manuel J., Parellada, Mara, Gonzalez-Pinto, Ana, Berrocoso, Esther, Bernardo, Miquel, Mas, Sergi, 2EPS Grp

المساهمون: Segura, Alex-Gonzalez Univ Barcelona, Dept Clin Fdn, Pharmacol Unit, Barcelona, Spain, Prohens, Llucia Univ Barcelona, Dept Clin Fdn, Pharmacol Unit, Barcelona, Spain, Mezquida, Gisela Univ Barcelona, Dept Clin Fdn, Pharmacol Unit, Barcelona, Spain, Mas, Sergi Univ Barcelona, Dept Clin Fdn, Pharmacol Unit, Barcelona, Spain, Segura, Alex-Gonzalez Inst Invest Biomed August Pi & Sunyer IDIBAPs, Barcelona, Spain, Prohens, Llucia Inst Invest Biomed August Pi & Sunyer IDIBAPs, Barcelona, Spain, Mezquida, Gisela Inst Invest Biomed August Pi & Sunyer IDIBAPs, Barcelona, Spain, Amoretti, Silvia Inst Invest Biomed August Pi & Sunyer IDIBAPs, Barcelona, Spain, Bioque, Miquel Inst Invest Biomed August Pi & Sunyer IDIBAPs, Barcelona, Spain, Bernardo, Miquel Inst Invest Biomed August Pi & Sunyer IDIBAPs, Barcelona, Spain, Mas, Sergi Inst Invest Biomed August Pi & Sunyer IDIBAPs, Barcelona, Spain, Mezquida, Gisela Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit BCSU, Barcelona, Spain, Amoretti, Silvia Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit BCSU, Barcelona, Spain, Bioque, Miquel Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit BCSU, Barcelona, Spain, Bernardo, Miquel Hosp Clin Barcelona, Neurosci Inst, Barcelona Clin Schizophrenia Unit BCSU, Barcelona, Spain, Mezquida, Gisela Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Amoretti, Silvia Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Bioque, Miquel Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Gurriaran-Bas, Xaquin Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Berge, Daniel Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Rodriguez-Jimenez, Roberto Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Pomarol-Clotet, Edith Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Ibanez, Angela Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Garcia-Portilla, Maria Paz Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Cuesta, Manuel J. Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Parellada, Mara Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Gonzalez-Pinto, Ana Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Berrocoso, Esther Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Bernardo, Miquel Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Mas, Sergi Ctr Invest Biomed Red Salud Mental CIBERSAM, Barcelona, Spain, Bioque, Miquel Univ Barcelona, Dept Med, Barcelona, Spain, Bernardo, Miquel Univ Barcelona, Dept Med, Barcelona, Spain, Ribeiro, Maria Complejo Hosp Navarra, Dept Psychiat, Pamplona, Spain, Cuesta, Manuel J. Complejo Hosp Navarra, Dept Psychiat, Pamplona, Spain, Ribeiro, Maria Navarra Inst Hlth Res, IdiSNA, Pamplona, Spain, Cuesta, Manuel J. Navarra Inst Hlth Res, IdiSNA, Pamplona, Spain, Gurriaran-Bas, Xaquin Univ Complutense, Hosp Gen Univ Gregorio Maranon, Sch Med,IiSGM, Inst Psychiat & Mental Hlth,Dept Child & Adolesce, Madrid, Spain, Parellada, Mara Univ Complutense, Hosp Gen Univ Gregorio Maranon, Sch Med,IiSGM, Inst Psychiat & Mental Hlth,Dept Child & Adolesce, Madrid, Spain, Rementeria, Lide Hosp Univ Alava, Dept Psychiat, Vitoria, Spain, Gonzalez-Pinto, Ana Hosp Univ Alava, Dept Psychiat, Vitoria, Spain, Rementeria, Lide Ctr Invest Biomed Red Salud Mental CIBERSAM, Vitoria, Spain, Gonzalez-Pinto, Ana Ctr Invest Biomed Red Salud Mental CIBERSAM, Vitoria, Spain, Rementeria, Lide BIOARABA Hlth Res Inst, Vitoria, Spain, Gonzalez-Pinto, Ana BIOARABA Hlth Res Inst, Vitoria, Spain, Berge, Daniel Hosp del Mar Med Res Inst IMIM, Barcelona, Spain, Berge, Daniel Autonomous Univ Barcelona, Barcelona, Spain, Rodriguez-Jimenez, Roberto Inst Invest Sanitaria Hosp 12 Octubre Imas12, Madrid, Spain, Rodriguez-Jimenez, Roberto Univ Complutense Madrid UCM, CogPsy Grp, Madrid, Spain, Roldan, Alexandra Hosp Santa Creu & Sant Pau, Psychiat Dept, Inst Invest Biomed St Pau IIB ST PAU, Barcelona, Spain, Pomarol-Clotet, Edith FIDMAG Germanes Hosp Res Fdn, Barcelona, Spain, Ibanez, Angela Univ Alcala, Hosp Univ Ramon y Cajal, Dept Psychiat, IRYCIS, Madrid, Spain, Usall, Judith Inst Recerca St Joan de Deu, Teaching Res & Innovat Unit, Parc Sanitari St Joan de Deu, Barcelona, Spain, Garcia-Portilla, Maria Paz Univ Oviedo, Dept Psychiat, Oviedo, Spain, Garcia-Portilla, Maria Paz Inst Invest Sanitaria Principado Asturias ISPA, Oviedo, Principality Of, Spain, Garcia-Portilla, Maria Paz Inst Univ Neurociencias Principado Asturias INEUR, Oviedo, Principality Of, Spain, Garcia-Portilla, Maria Paz Serv Salud Principado Asturias SESPA Oviedo, Oviedo, Spain, Berrocoso, Esther Univ Cadiz, Dept Psychol, Neuropsychopharmacol & Psychobiol Res Grp, Cadiz, Spain, Berrocoso, Esther Hosp Univ Puerta del Mar, Inst Invest & Innovac Biomed Cadiz, INiB, Cadiz, Spain, Carlos III Healthcare Institute, Spanish Ministry of Science, Innovation and Universities, European Regional Development Fund (ERDF/FEDER), Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), CERCA Program, Catalan Government, Secretariat of Universities and Research of the Department of Enterprise and Knowledge, Institut de Neurociencies, Universitat de Barcelona

مصطلحات موضوعية: Leukocyte telomere length, Unaffected siblings, Age, Psychosis

الوصف: The main objective of the present study was to investigate the association between several epigenetic clocks, covering different aspects of aging, with schizophrenia relapse evaluated over a 3-year follow-up period in a cohort of ninety-one first-episode schizophrenia patients. Genome-wide DNA methylation was profiled and four epigenetic clocks, including epigenetic clocks of chronological age, mortality and telomere length were calculated. Patients that relapsed during the follow-up showed epigenetic acceleration of the telomere length clock (p=0.030). Shorter telomere length was associated with cognitive performance (working memory, r=0.31 p=0.015; verbal fluency, r=0.28 p=0.028), but no direct effect of cognitive function or symptom severity on relapse was detected. The results of the present study suggest that epigenetic age acceleration could be involved in the clinical course of schizophrenia and could be a useful marker of relapse when measured in remission stages.

العلاقة: http://hdl.handle.net/10668/19562Test; https://www.nature.com/articles/s41537-022-00268-2.pdfTest; 928398100001

الإتاحة: https://doi.org/10.1038/s41537-022-00268-2Test
http://hdl.handle.net/10668/19562Test
https://www.nature.com/articles/s41537-022-00268-2.pdfTest

المؤلفون: Baeza, Inmaculada, de la Serna, Elena, Mezquida, Gisela, Cuesta, Manuel J., Vieta, Eduard, Amoretti, Silvia, Lobo, Antonio, González-Pinto, Ana, Díaz-Caneja, Covadonga M., Corripio, Iluminada, Valli, Isabel, Puig, Olga, Mané, Anna, Bioque, Miquel, Ayora, Miriam, Bernardo, Miquel, Castro-Fornieles, Josefina, García-Rizo, Clemente, González-Díaz, Jairo, de Matteis, Mario, de Diego, Héctor, Grasa, Eva, Roldán, Alejandra, Zorrilla, Iñaki, García-Corres, Edurne, Ruíz-Lázaro, Pedro M, de-la-Cámara, Concepción, Rivero, Olga, Escarti, María José, Casanovas, Francesc, Toll, Alba, Verdolini, Norma, Sagué-Vilabella, Maria, Sugranyes, Gisela, Ilzarbe, Daniel, Contreras, Fernando, González-Blanco, Leticia, García-Portilla, María Paz, Gutierrez, Miguel, Zabala, Arantzazu, Rodríguez-Jiménez, Roberto, Sánchez-Pastor, Luis, Usall, Judith, Butjosa, Anna, Pomarol, Edith, Sarró, Salvador, Ibáñez, Angela, Sánchez-Torres, Ana Maria, Balanzá-Martínez, Vicent

الوصف: To assess the role of age (early onset psychosis-EOP < 18 years vs. adult onset psychosis-AOP) and diagnosis (schizophrenia spectrum disorders-SSD vs. bipolar disorders-BD) on the duration of untreated psychosis (DUP) and prodromal symptoms in a sample of patients with a first episode of psychosis. 331 patients with a first episode of psychosis (7–35 years old) were recruited and 174 (52.6%) diagnosed with SSD or BD at one-year follow-up through a multicenter longitudinal study. The Symptom Onset in Schizophrenia (SOS) inventory, the Positive and Negative Syndrome Scale and the structured clinical interviews for DSM-IV diagnoses were administered. Generalized linear models compared the main effects and group interaction. 273 AOP (25.2 ± 5.1 years; 66.5% male) and 58 EOP patients (15.5 ± 1.8 years; 70.7% male) were included. EOP patients had significantly more prodromal symptoms with a higher frequency of trouble with thinking, avolition and hallucinations than AOP patients, and significantly different median DUP (91 [33–177] vs. 58 [21–140] days; Z = − 2.006, p = 0.045). This was also significantly longer in SSD vs. BD patients (90 [31–155] vs. 30 [7–66] days; Z = − 2.916, p = 0.004) who, moreover had different profiles of prodromal symptoms. When assessing the interaction between age at onset (EOP/AOP) and type of diagnosis (SSD/BD), avolition was significantly higher (Wald statistic = 3.945; p = 0.047), in AOP patients with SSD compared to AOP BD patients (p = 0.004). Awareness of differences in length of DUP and prodromal symptoms in EOP vs. AOP and SSD vs. BD patients could help improve the early detection of psychosis among minors. Evaluar el papel de la edad (psicosis de inicio temprano-EOP <18 años versus psicosis de inicio en la edad adulta-AOP) y el diagnóstico (trastornos del espectro de la esquizofrenia-SSD versus trastornos bipolares-TB) en la duración de la psicosis no tratada (DUP) y los síntomas prodrómicos. en una muestra de pacientes con un primer episodio de psicosis. Se reclutaron 331 ...

وصف الملف: application/pdf

العلاقة: info:eu-repo/grantAgreement/ES/MINECO-ISCIII-FEDER/PI11-00325; info:eu-repo/grantAgreement/ES/MINECO-ISCIII-FEDER/PI14-00612; info:eu-repo/grantAgreement/ES/MINECO-ISCIII/PI-080208-PEPs study; http://zaguan.unizar.es/record/126276Test

الإتاحة: https://doi.org/10.1007/s00787-023-02196-7Test
http://zaguan.unizar.es/record/126276Test

المؤلفون: Hidalgo Figueroa, María, Salazar, Alejandro, Romero López-Alberca, Cristina, MacDowell, Karina S., García Bueno, Borja, Bioque, Miquel, Bernardo, Miquel, Parellada, Mara, González Pinto, Ana, García-Portilla González, María Paz, Lobo, A., Rodríguez Jiménez, R., Berrocoso, E., Leza, J.C.

المصدر: WOS:000790865600001

الوصف: This work was supported by CIBERSAM Intramural Projects 2010 (P02) “Flamm- PEPs, inflammatory alterations in schizophrenia: search of biological markers in first-psychotic episodes,” Spanish Ministry of Economy and Competiveness, Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias (PI1100325). R.R.J. was supported by the Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias/FEDER (PI19/00766) and by the Madrid Regional Government (S2017/BMD-3740). M.P.G.-P. was supported by the Government of the Principality of Asturias (PCTI-2018–2022 IDI/2018/235). M.H.-F. was supported by the 2014-2020 ERDF Operational Programme and by the Department of Economy, Knowledge, Business and University of the Regional Government of Andalusia (FEDER-UCA18-106933).

العلاقة: International Journal of Neuropsychopharmacology; MINECO/PI1100325; IDI/2018/235; http://dx.doi.org/10.1093/ijnp/pyac023Test; International Journal of Neuropsychopharmacology, 25(8), p. 666-677 (2022); doi:10.1093/ijnp/pyac023; http://hdl.handle.net/10651/66169Test

الإتاحة: https://doi.org/10.1093/ijnp/pyac023Test
http://hdl.handle.net/10651/66169Test

المؤلفون: Llorca‑Bofí, Vicent, Bioque, Miquel, Font, Maria, Gich, Ignasi, Mur, Maria

مصطلحات موضوعية: Schizophrenia, C-Reactive Protein, Inflammatory ratios, Neutrophil-Lymphocyte Ratio, Monocyte-Lymphocyte Ratio, Platelet-Lymphocyte Ratio

الوصف: C-reactive protein (CRP) and inflammatory ratios have been proposed to study immune dysregulation in schizophrenia. Nevertheless, links between CRP and inflammatory ratios in acute SCZ inpatients have been understudied. This study investigated the relationship between CRP and inflammatory ratios (Neutrophil-Lymphocyte Ratio [NRL], Platelet-Lymphocyte Ratio [PLR], Monocyte-Lymphocyte ratio [MLR] and Basophil-Lymphocyte Ratio [BLR]) in a total of 698 acute SCZ inpatients; and analysed how this relationship is affected by sex and type of episode. CRP correlated with NLR (rs = 0.338, p < 0.001), PLR (rs = 0.271, p < 0.001) and MLR (rs = 0.148, p < 0.001) but not with BLR (rs = 0.059, p = 0.121). Multiple lineal regression analysis showed that high levels of NLR, MLR and PLR but not BLR were independently associated with high CRP levels. No sex-related variations were found. Significant associations were maintained for NLR and MLR in first-episode and multiepisode SCZ, although the strength of the association was stronger in multiepisode SCZ. Again, no sex-related differences were found in these associations. In conclusion, inflammatory ratios were low to moderately associated with CRP in acute SCZ inpatients. NLR and multiepisode SCZ showed the highest associations with CRP. Future studies should consider inflammatory ratios not as a substitute for CRP but as a complementary biomarker.

العلاقة: Reproducció del document publicat a https://doi.org/10.1016/j.jpsychires.2023.07.023Test; Journal of Psychiatric Research, 2023, vol. 165, p. 191-196; https://doi.org/10.1016/j.jpsychires.2023.07.023Test; https://repositori.udl.cat/handle/10459.1/464226Test

الإتاحة: https://doi.org/10.1016/j.jpsychires.2023.07.023Test
https://repositori.udl.cat/handle/10459.1/464226Test

المؤلفون: Rodríguez, Natalia, Gassó, P., Martínez-Pinteño, A., González Segura, Álex, Mezquida, G., Moreno-Izco, Lucia, González-Peñas, J., Zorrilla, Iñaki, Martin, Marta, Rodriguez-Jimenez, R., Corripio, I., Sarró, S., Ibáñez, A., Butjosa, Anna, Contreras, Fernando, Bioque, Miquel, Cuesta, Manuel Jesús, Parellada, M., González-Pinto, A., Berrocoso Domínguez, Esther María, Bernardo, Miquel, Mas, Sergi, 2EPS group

المساهمون: Psicología

المصدر: Schizophrenia, Vol. 8, Núm. 1

الوصف: A better understanding of schizophrenia subtypes is necessary to stratify the patients according to clinical attributes. To explore the genomic architecture of schizophrenia symptomatology, we analyzed blood co-expression modules and their association with clinical data from patients in remission after a first episode of schizophrenia. In total, 91 participants of the 2EPS project were included. Gene expression was assessed using the Clariom S Human Array. Weighted-gene co-expression network analysis (WGCNA) was applied to identify modules of co-expressed genes and to test its correlation with global functioning, clinical symptomatology, and premorbid adjustment. Among the 25 modules identified, six modules were significantly correlated with clinical data. These modules could be clustered in two groups according to their correlation with clinical data. Hub genes in each group showing overlap with risk genes for schizophrenia were enriched in biological processes related to metabolic processes, regulation of gene expression, cellular localization and protein transport, immune processes, and neurotrophin pathways. Our results indicate that modules with significant associations with clinical data showed overlap with gene sets previously identified in differential gene-expression analysis in brain, indicating that peripheral tissues could reveal pathogenic mechanisms. Hub genes involved in these modules revealed multiple signaling pathways previously related to schizophrenia, which may represent the complex interplay in the pathological mechanisms behind the disease. These genes could represent potential targets for the development of peripheral biomarkers underlying illness traits in clinical remission stages after a first episode of schizophrenia.

وصف الملف: application/pdf

العلاقة: info:eu-repo/grantAgreement/ES/ISCIII/PI08-0208; info:eu-repo/grantAgreement/ES/MINECO-ISCIII-FEDER/PI11-00325; info:eu-repo/grantAgreement/ES/MINECO-ISCIII-FEDER/PI14-00612; http://hdl.handle.net/10498/27853Test

الإتاحة: https://doi.org/10.1038/s41537-022-00215-1Test
http://hdl.handle.net/10498/27853Test

المؤلفون: González Segura, Álex, Prohens, Llucia, Mezquida, G., Amoretti, Silvia, Bioque, Miquel, Ribeiro, M., Gurriarán-Bas, Xaquin, Rementería, Lide, Berge, Daniel, Rodriguez-Jimenez, R., Roldán, Alexandra, Pomarol-Clotet, Edit, Ibáñez, Angela, Usall, J., García Portilla, María Paz, Cuesta, Manuel J., Parellada, M., González-Pinto, A., Berrocoso Domínguez, Esther María, Bernardo, Miquel, Mas, Sergi, 2EPS group

المساهمون: Psicología

المصدر: Schizophrenia, Vol. 8, Núm. 1

الوصف: The main objective of the present study was to investigate the association between several epigenetic clocks, covering different aspects of aging, with schizophrenia relapse evaluated over a 3-year follow-up period in a cohort of ninety-one first-episode schizophrenia patients. Genome-wide DNA methylation was profiled and four epigenetic clocks, including epigenetic clocks of chronological age, mortality and telomere length were calculated. Patients that relapsed during the follow-up showed epigenetic acceleration of the telomere length clock (p=0.030). Shorter telomere length was associated with cognitive performance (working memory, r=0.31 p=0.015; verbal fluency, r=0.28 p=0.028), but no direct effect of cognitive function or symptom severity on relapse was detected. The results of the present study suggest that epigenetic age acceleration could be involved in the clinical course of schizophrenia and could be a useful marker of relapse when measured in remission stages.

وصف الملف: application/pdf

العلاقة: info:eu-repo/grantAgreement/MINECO//PI14%2F00612/ES/Estudio de aplicabilidad clínica de un modelo predictivo de recaídas en primeros episodios de esquizofrenia/; http://hdl.handle.net/10498/27935Test

الإتاحة: https://doi.org/10.1038/s41537-022-00268-2Test
http://hdl.handle.net/10498/27935Test

المؤلفون: Hidalgo-Figueroa, Maria, Salazar, Alejandro, Romero-López-Alberca, Cristina, MacDowell, Karina S, García-Bueno, Borja, Bioque, Miquel, Bernardo, Miquel, Parellada, Mara, González-Pinto, Ana, García-Portilla, M Paz, Lobo, Antonio, Rodriguez-Jimenez, Roberto, Berrocoso, Esther, Leza, Juan C

المساهمون: Spanish Ministry of Economy and Competiveness, Madrid Regional Government, Government of the Principality of Asturias, ERDF, Department of Economy, Knowledge, Business

المصدر: International Journal of Neuropsychopharmacology ; volume 26, issue 11, page 796-807 ; ISSN 1461-1457 1469-5111

مصطلحات موضوعية: Pharmacology (medical), Psychiatry and Mental health, Pharmacology

الوصف: Background The clinical debut of schizophrenia is frequently a first episode of psychosis (FEP). As such, there is considerable interest in identifying associations between biological markers and clinical or cognitive characteristics that help predict the progression and outcome of FEP patients. Previous studies showed that high prolactin, low oxytocin, and high homocysteine are factors associated with FEP 6 months after diagnosis, at which point plasma levels were correlated with some clinical and cognitive characteristics. Methods We reexamined 75 patients at 12 months after diagnosis to measure the evolution of these molecules and assess their association with clinical features. Results At follow-up, FEP patients had lower prolactin levels than at baseline, and patients treated with risperidone or paliperidone had higher prolactin levels than patients who received other antipsychotic agents. By contrast, no changes in oxytocin and homocysteine plasma levels were observed between the baseline and follow-up. In terms of clinical features, we found that plasma prolactin and homocysteine levels were correlated with the severity of the psychotic symptoms in male FEP patients, suggesting that they might be factors associated with psychotic symptomatology but only in men. Together with oxytocin, these molecules may also be related to sustained attention, verbal ability, and working memory cognitive domains in FEP patients. Conclusion This study suggests that focusing on prolactin, oxytocin, and homocysteine at a FEP may help select adequate pharmacological treatments and develop new tools to improve the outcome of these patients, where sex should also be borne in mind.

الإتاحة: https://doi.org/10.1093/ijnp/pyad051Test
https://academic.oup.com/ijnp/article-pdf/26/11/796/53799854/pyad051.pdfTest